from Cosmo Pharmaceuticals N.V. (isin : NL0011832936)
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
Cosmo Pharmaceuticals N.V. / Key word(s): Half Year Results
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
05.07.2023 / 06:15 GMT/BST
Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wednesday, 26 July 2023 at 07:00 am CEST.
Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation which will follow at 2:00 pm CEST with Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the financial and operating results as well as the next milestones of the Company.
Live conference call and video webcast presentation:
Date: Wednesday, 26 July 2023
Time: 2:00 pm CEST
Participant webcast link: Chrome (recommended) or Firefox
https://media.choruscall.eu/mediaframe/webcast.html?webcastid=cjTWeUeO
Please note that there is a function to type in your questions via webcast.
Via phone:
Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
The media release as well as the Half-Year Report 2023 will be available for download as of 07:00 am CEST on 26 July 2023 at www.cosmopharma.com.
Replay
The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.
About Cosmo
Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally by selected partners including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/ Relafalk® and Winlevi®. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ which uses artificial intelligence to help detect potential signs of colon cancer. The company also has a rich development pipeline. For additional information on Cosmo and its products, please visit www.cosmopharma.com.
Contact:
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
End of Media Release
| Language: | English |
| Company: | Cosmo Pharmaceuticals N.V. |
| Riverside 2, Sir John Rogerson’s | |
| Dublin 2 Dublin | |
| Ireland | |
| Phone: | + 353 1 817 0370 |
| E-mail: | info@cosmopharma.com |
| Internet: | https://www.cosmopharma.com/ |
| ISIN: | NL0011832936 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1672751 |
| End of News | EQS News Service |
1672751 05.07.2023 GMT/BST